Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
1294 | 8163 | 32.9 | 42% |
Classes in level above (level 3) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
576 | 13579 | FOOD AND DRUG LAW JOURNAL//CIENCIA & SAUDE COLETIVA//SAUDE E SOCIEDADE |
Classes in level below (level 1) |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | FOOD AND DRUG LAW JOURNAL | Journal | 420 | 55% | 6% | 526 |
2 | GENERIC SUBSTITUTION | Author keyword | 89 | 75% | 1% | 65 |
3 | DIRECT TO CONSUMER ADVERTISING | Author keyword | 66 | 65% | 1% | 62 |
4 | CONFLICT OF INTEREST | Author keyword | 63 | 32% | 2% | 163 |
5 | GENERIC DRUGS | Author keyword | 48 | 42% | 1% | 88 |
6 | PHARMACEUTICAL INDUSTRY | Author keyword | 42 | 22% | 2% | 165 |
7 | ORPHAN DRUGS | Author keyword | 40 | 46% | 1% | 64 |
8 | GENERIC MEDICINES | Author keyword | 37 | 73% | 0% | 29 |
9 | DRUG INDUSTRY | Author keyword | 36 | 44% | 1% | 63 |
10 | REFERENCE PRICING | Author keyword | 31 | 73% | 0% | 24 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | GENERIC SUBSTITUTION | 89 | 75% | 1% | 65 | Search GENERIC+SUBSTITUTION | Search GENERIC+SUBSTITUTION |
2 | DIRECT TO CONSUMER ADVERTISING | 66 | 65% | 1% | 62 | Search DIRECT+TO+CONSUMER+ADVERTISING | Search DIRECT+TO+CONSUMER+ADVERTISING |
3 | CONFLICT OF INTEREST | 63 | 32% | 2% | 163 | Search CONFLICT+OF+INTEREST | Search CONFLICT+OF+INTEREST |
4 | GENERIC DRUGS | 48 | 42% | 1% | 88 | Search GENERIC+DRUGS | Search GENERIC+DRUGS |
5 | PHARMACEUTICAL INDUSTRY | 42 | 22% | 2% | 165 | Search PHARMACEUTICAL+INDUSTRY | Search PHARMACEUTICAL+INDUSTRY |
6 | ORPHAN DRUGS | 40 | 46% | 1% | 64 | Search ORPHAN+DRUGS | Search ORPHAN+DRUGS |
7 | GENERIC MEDICINES | 37 | 73% | 0% | 29 | Search GENERIC+MEDICINES | Search GENERIC+MEDICINES |
8 | DRUG INDUSTRY | 36 | 44% | 1% | 63 | Search DRUG+INDUSTRY | Search DRUG+INDUSTRY |
9 | REFERENCE PRICING | 31 | 73% | 0% | 24 | Search REFERENCE+PRICING | Search REFERENCE+PRICING |
10 | BRAND NAME DRUG | 31 | 92% | 0% | 12 | Search BRAND+NAME+DRUG | Search BRAND+NAME+DRUG |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | PHARMACEUTICAL INDUSTRY | 111 | 29% | 4% | 330 |
2 | DRUG COMPANIES | 77 | 65% | 1% | 73 |
3 | CONFLICTS OF INTEREST | 74 | 32% | 2% | 189 |
4 | GIFTS | 68 | 50% | 1% | 98 |
5 | PRESCRIPTION DRUGS | 44 | 29% | 2% | 128 |
6 | INTEREST POLICIES | 33 | 83% | 0% | 19 |
7 | GENERIC ENTRY | 32 | 88% | 0% | 15 |
8 | PHARMACEUTICAL SALES REPRESENTATIVES | 29 | 75% | 0% | 21 |
9 | PHARMACEUTICAL ADVERTISEMENTS | 28 | 64% | 0% | 27 |
10 | REPRESENTATIVES | 26 | 25% | 1% | 91 |
Journals |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | FOOD AND DRUG LAW JOURNAL | 420 | 55% | 6% | 526 |
2 | NEW GENETICS AND SOCIETY | 6 | 13% | 1% | 42 |
3 | THERAPEUTIC INNOVATION & REGULATORY SCIENCE | 4 | 13% | 0% | 30 |
4 | BIOTECHNOLOGY LAW REPORT | 4 | 16% | 0% | 23 |
5 | BIOSOCIETIES | 2 | 11% | 0% | 18 |
6 | JOURNAL OF INTELLECTUAL PROPERTY RIGHTS | 1 | 11% | 0% | 10 |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
Physicians and the pharmaceutical industry - Is a gift ever just a gift? | 2000 | 640 | 39 | 95% |
Scope and impact of financial conflicts of interest in biomedical research - A systematic review | 2003 | 782 | 55 | 60% |
The cost of drug development: A systematic review | 2011 | 59 | 8 | 100% |
Drug discovery in pharmaceutical industry: productivity challenges and trends | 2012 | 50 | 12 | 67% |
Models for open innovation in the pharmaceutical industry | 2013 | 15 | 3 | 100% |
Clinical Equivalence of Generic and Brand-Name Drugs Used in Cardiovascular Disease A Systematic Review and Meta-analysis | 2008 | 119 | 66 | 55% |
Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival | 2012 | 82 | 21 | 29% |
Industry sponsorship and research outcome | 2012 | 43 | 112 | 52% |
Industry Relationships Among Academic Institutional Review Board Members Changes From 2005 Through 2014 | 2015 | 1 | 14 | 93% |
Orphan drug development: an economically viable strategy for biopharma R&D | 2012 | 25 | 11 | 73% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | OFF ORPHAN PROD DEV | 17 | 70% | 0.2% | 14 |
2 | CRHAM | 17 | 100% | 0.1% | 8 |
3 | TUFTS STUDY DRUG DEV | 16 | 48% | 0.3% | 25 |
4 | EDMOND J SAFRA ETH | 15 | 44% | 0.3% | 27 |
5 | SCI TECHNOL INNOVAT NEGLECTED DIS | 12 | 86% | 0.1% | 6 |
6 | OFF PHARMACEUT IND | 11 | 100% | 0.1% | 6 |
7 | PROGRAM LIFE SCI ETH POLICY | 8 | 70% | 0.1% | 7 |
8 | STUDY DRUG DEV | 8 | 42% | 0.2% | 15 |
9 | PROGRAM STEM CELLS SOC | 7 | 64% | 0.1% | 7 |
10 | MCLAUGHLIN ROTMAN GLOBAL HLTH | 7 | 23% | 0.3% | 25 |
Related classes at same level (level 2) |